ABIONYX Pharma Reaches Another Key Milestone in the Industrialization of CER-001 by Entering into a Strategic Partnership with TEXCELL (ABL Diagnostics) for the Viral Safety and Clearance of Biologics

TOULOUSE, France & FULLERTON, Calif.–(BUSINESS WIRE)–Regulatory News: ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I-based technology platform, announces the establishment of a strategic partnership with TEXCELL, a division of ABL Diagnostics, for the viral safety and clearance testing of its biopharmaceutical development. This collaboration marks a